Sangita Ghosh
Chief Tech/Sci/R&D Officer chez CHEMOCENTRYX, INC.
Profil
Sangita Ghosh is a professional who has worked in various pharmaceutical companies.
She is currently the Senior Vice President-Technical Operations at ChemoCentryx, Inc. Prior to this, she worked as the Vice President-Pharmaceutical Development at Adamas Pharmaceuticals LLC from 2012 to 2018 and as the VP-Pharmaceutical Development & Manufacturing at Spruce Biosciences, Inc. from 2018 to 2020.
She also worked as a Senior Director at Transcept Pharma, Inc. She holds a doctorate degree from the Indian Institute of Science and a graduate degree from the Indian Institute of Technology Kanpur.
Postes actifs de Sangita Ghosh
| Sociétés | Poste | Début |
|---|---|---|
| CHEMOCENTRYX, INC. | Chief Tech/Sci/R&D Officer | 01/03/2020 |
Anciens postes connus de Sangita Ghosh
| Sociétés | Poste | Fin |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Corporate Officer/Principal | 01/01/2020 |
| ADAMAS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2018 |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Director/Board Member | - |
Formation de Sangita Ghosh
| Indian Institute of Science | Doctorate Degree |
| Indian Institute of Technology Kanpur | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
